NCT02929667View on ClinicalTrials.gov

Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 16, 2017

Primary Completion Date

March 6, 2019

Study Completion Date

March 6, 2019

Conditions
EpilepsySUDEP
Interventions
DRUG

Fluoxetine

Standard 6 weeks titration, starting 10 mg per day.

DRUG

Placebo

Standard 6 weeks titration.

Trial Locations (2)

52242

The Univeristy of Iowa Hospitals and Clinics, Iowa City

Univeristy of Iowa Hospitals and Clinics, Iowa City

All Listed Sponsors
lead

Rup Kamal Sainju

OTHER

NCT02929667 - Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI | Biotech Hunter | Biotech Hunter